SAHAR AZIM: Open Payments
NPI 1811428477 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,645 in 89 payments from 17 companies in 2025. Trend: 2023 $511 · 2024 $603 · 2025 $1,645
Food & beverage: $1,645
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $310 |
| Janssen Pharmaceuticals, Inc | 8 | $280 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $203 |
| E.R. Squibb & Sons, L.L.C. | 5 | $123 |
| Neurocrine BioSciences, Inc. | 5 | $111 |
| Axsome Therapeutics, Inc. | 4 | $87 |
| Teva Pharmaceuticals USA, Inc. | 3 | $85 |
| Alkermes, Inc. | 3 | $82 |
| ABBVIE INC. | 4 | $74 |
| Almatica Pharma LLC | 4 | $59 |
Products named: REXULTI, SPRAVATO, CAPLYTA, COBENFY, INGREZZA, ABILIFY ASIMTUFII, Auvelity, ARISTADA.
Industry payments across NV — which companies pay providers there.
